CD8A and neoplasm: Deep IL-15 was evaluated in an adoptive T cell therapy model by treatment of B16-F10 tumor-bearing mice with PMEL CD8+ T (PMEL) cells (10-27 x 106), carrying up to 158 μg of Deep IL-15 (>15-fold the maximum tolerated dose, MTD, of IL15-Fc).